Your browser doesn't support javascript.
loading
Design and rationale of the INSYTE study: A randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal microbiota in non-alcoholic fatty liver disease.
Scorletti, Eleonora; Afolabi, Paul R; Miles, Elizabeth A; Smith, Debbie E; Almehmadi, Amal; Alshathry, Albandri; Moyses, Helen E; Clough, Geraldine F; Wright, Mark; Patel, Janisha; Bindels, Laure; Delzenne, Nathalie M; Calder, Philip C; Byrne, Christopher D.
Afiliación
  • Scorletti E; Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK; National Institute for Health Research Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton National Health Service (NHS) Foundation Trust, So
  • Afolabi PR; National Institute for Health Research Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton National Health Service (NHS) Foundation Trust, Southampton, UK.
  • Miles EA; Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Smith DE; Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK; National Institute for Health Research Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton National Health Service (NHS) Foundation Trust, So
  • Almehmadi A; Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Alshathry A; Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Moyses HE; National Institute for Health Research Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton National Health Service (NHS) Foundation Trust, Southampton, UK.
  • Clough GF; Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Wright M; Hepatology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Patel J; Hepatology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Bindels L; Metabolism and Nutrition Research Group, Louvain Drug Research Institute, Université Catholique de Louvain, Brussels, Belgium.
  • Delzenne NM; Metabolism and Nutrition Research Group, Louvain Drug Research Institute, Université Catholique de Louvain, Brussels, Belgium.
  • Calder PC; Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK; National Institute for Health Research Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton National Health Service (NHS) Foundation Trust, So
  • Byrne CD; Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK; National Institute for Health Research Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton National Health Service (NHS) Foundation Trust, So
Contemp Clin Trials ; 71: 113-123, 2018 08.
Article en En | MEDLINE | ID: mdl-29787859
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of fat-related conditions ranging from simple fatty liver, to non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis. There is growing evidence that NAFLD is a multisystem disease, affecting several extra-hepatic organs and regulatory pathways. Furthermore, since the gut and liver are linked anatomically via the portal vein, disturbances of the gut microbiota (dysbiosis) can affect the liver. OBJECTIVES: In patients with NAFLD, we are testing the effects of a synbiotic which is the combination of a prebiotic (fructooligosaccharides; 4 g/day) and a probiotic (Bifidobacterium animalis subsp. lactis BB-12 at a minimum of 10 billion CFU/day) on a) liver fat percentage, b) NAFLD fibrosis algorithm scores, c) gut microbiota composition. Additionally, there will be several hypothesis-generating secondary outcomes to understand the metaorganismal pathways that influence the development and progression of NAFLD, type 2 diabetes, and cardiovascular risk. DESIGN: In a randomised double-blind placebo-controlled trial, 104 participants were randomised to 10-14 months intervention with either synbiotic (n = 55) or placebo (n = 49). Recruitment was completed in April 2017 and the last study visit will be completed by April 2018. METHODS: Change in gut microbiota composition will be assessed using 16S ribosomal RNA gene sequencing. Change in mean liver fat percentage will be quantified by magnetic resonance spectroscopy (MRS). In addition, change in liver fat severity will be measured using two NAFLD fibrosis algorithm scores. The INSYTE study was approved by the local ethics committee (REC: 12/SC/0614) and is registered at www.clinicaltrials.gov as NCT01680640.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Oligosacáridos / ARN Ribosómico 16S / Tracto Gastrointestinal / Enfermedad del Hígado Graso no Alcohólico / Microbioma Gastrointestinal / Bifidobacterium animalis / Hígado Tipo de estudio: Clinical_trials / Etiology_studies Aspecto: Ethics Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Contemp Clin Trials Asunto de la revista: MEDICINA / TERAPEUTICA Año: 2018 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Oligosacáridos / ARN Ribosómico 16S / Tracto Gastrointestinal / Enfermedad del Hígado Graso no Alcohólico / Microbioma Gastrointestinal / Bifidobacterium animalis / Hígado Tipo de estudio: Clinical_trials / Etiology_studies Aspecto: Ethics Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Contemp Clin Trials Asunto de la revista: MEDICINA / TERAPEUTICA Año: 2018 Tipo del documento: Article Pais de publicación: Estados Unidos